INS and metabolic syndrome: lactis BPL1-derived lipoteichoic acids (LTAs) function as novel lipid modulators with fat-reducing capabilities through the insulin-like signaling pathway (IGF-1) and prevent metabolic syndrome and diabetes-related disorders [243].